Abstract
•Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy liver disease, characterised by pruritus and increased total serum bile acids (TSBA), Australian incidence 0.6–0.7%.
•ICP is diagnosed by non-fasting TSBA ≥19 μmol/L in a pregnant woman with pruritus without rash without a known pre-existing liver disorder.
•Peak TSBA ≥40 and ≥100 μmol/L identify severe and very severe disease respectively, associated with spontaneous preterm birth when severe, and with stillbirth, when very severe.
•Benefit-vs-risk for iatrogenic preterm birth in ICP remains uncertain.
•Ursodeoxycholic acid remains the best pharmacotherapy preterm, improving perinatal outcome and reducing pruritus, although it has not been shown to reduce stillbirth.
| Original language | English |
|---|---|
| Pages (from-to) | 656-665 |
| Number of pages | 10 |
| Journal | Australian and New Zealand Journal of Obstetrics and Gynaecology |
| Volume | 63 |
| Issue number | 5 |
| Early online date | 11 Jul 2023 |
| DOIs | |
| Publication status | Published - Oct 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- pregnancy
- pruritus
- stillbirth
- total serum bile acids
- ursodeoxycholic acid
Fingerprint
Dive into the research topics of 'Intrahepatic cholestasis of pregnancy – Diagnosis and management: A consensus statement of the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ): Executive summary'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver